Phase IIb Clinical Trial Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Phase IIb Clinical Trial

Health Care Term

Phase IIb clinical trials are a type of clinical study that is conducted as a part of the drug development process to assess the safety and effectiveness of a drug candidate. These trials typically involve a larger group of patients than Phase IIa trials and are designed to explore the optimal dose, dosing regimen, and potential side effects of the drug.

The Phase IIb clinical trials are usually randomized and double-blinded, meaning that the patients and the researchers do not know who is receiving the actual drug and who is receiving a placebo. The primary endpoint of Phase IIb clinical trials is usually efficacy, which is measured by evaluating the therapeutic response of the patients to the treatment.

These trials are crucial in the drug development process as they provide valuable information about the drug*s safety profile and potential benefits. The data collected from these trials also helps researchers and regulators make decisions about whether to move the drug candidate to the next phase of clinical development.

In the healthcare industry, Phase IIb clinical trials are used by pharmaceutical companies to gather data that can be submitted to regulatory agencies such as the Food and Drug Administration (FDA) for approval. Once a drug candidate has successfully completed all phases of clinical trials, it can be approved for use in the market and prescribed by healthcare providers.

In summary, Phase IIb clinical trials are a critical part of the drug development process and play a significant role in the healthcare industry by providing crucial information about the safety and effectiveness of drug candidates.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P